Faron Pharmaceuticals' (LON:FARN) chief executive Dr Markku Jalkanen joins Proactive London's Katie Pilbeam about their two key flagship programs, Clevegen and Traumakine.
Clevegen (bexmarilimab), Faron's wholly-owned, novel precision cancer immunotherapy candidate, is in Phase I/II development for difficult-to-treat cancers.
Meanwhile, the company is on track to initiate a Faron-sponsored trial investigating the potential of its intravenous (IV) interferon beta-1a therapy Traumakine to treat the Coronavirus (COVID-19).